Core Viewpoint - A class action lawsuit has been filed against Lakeland Industries, Inc. for securities fraud, alleging that the company made false and misleading statements regarding its business operations and financial results during the Class Period from December 1, 2023, to December 9, 2025 [1]. Group 1: Lawsuit Details - The lawsuit claims that Lakeland was facing significant issues with its Pacific Helmets and Jolly businesses, including shipping delays, production issues, and a slower rollout of new products [1]. - Defendants allegedly overstated the positive impact of these businesses on Lakeland's financial results and the overall strength of their operations [1]. - The lawsuit indicates that Lakeland's financial results were deteriorating due to tariff-related headwinds, certification delays, and material flow issues in its acquired businesses [1]. Group 2: Financial Guidance and Public Statements - The defendants are accused of overstating the effectiveness of their tariff mitigation measures and their "small, strategic, and quick" M&A strategy [1]. - As a result of the aforementioned issues, the financial guidance provided by the defendants was deemed unreliable [1]. - The lawsuit asserts that the public statements made by the defendants were materially false and misleading throughout the Class Period [1].

Core Viewpoint - Driven Brands Holdings Inc. is under investigation for potential claims due to significant financial reporting errors that led to a 30% drop in its stock price [1] Financial Reporting Issues - Driven Brands delayed its fourth-quarter release due to material errors in financial statements for fiscal years 2023 and 2024 [1] - The company disclosed that its previously issued financial statements should not be relied upon and require restatement [1] - Errors identified include lease recording issues affecting right of use assets and liabilities, cash account discrepancies leading to overstatements of cash and revenue, and overstated company-operated store expenses [1] Internal Control Weaknesses - Driven Brands identified material weaknesses in internal control over financial reporting [1] - The Report of its Independent Registered Public Accounting Firm on the financial statements and internal control should not be relied upon [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. between September 24, 2025, and October 31, 2025, about the upcoming lead plaintiff deadline on April 13, 2026, for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3]. - To serve as lead plaintiff, individuals must file with the court by April 13, 2026, acting on behalf of other class members [3]. Group 2: Case Background - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding its Pivotal Study for a drug candidate aimed at Huntington's Disease, including FDA approval status and the potential delay in its Biologics License Application (BLA) timeline [5]. - The defendants allegedly downplayed the likelihood of needing additional studies, which led to misleading statements about uniQure's business and prospects [5]. - The lawsuit claims that when the true details became known, investors suffered damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in BlackRock TCP Capital Corp. Lawsuit - TCPC [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BlackRock TCP Capital Corp. ("BlackRock TCP" or the "Company") (NASDAQ: TCPC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BlackRock TCP investors who were adversely affected by alleged securities f ...

Shareholders that lost money on PayPal Holdings, Inc.(PYPL) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in PayPal Holdings, Inc. ("PayPal" or the "Company") (NASDAQ: PYPL) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of PayPal investors who were adversely affected by alleged securities fraud between February ...

Shareholders that lost money on Varonis Systems, Inc.(VRNS) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Varonis Systems, Inc. ("Varonis" or the "Company") (NASDAQ: VRNS) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Varonis investors who were adversely affected by alleged securities fraud between Februar ...

Levi & Korsinsky Investigates Whether Ralliant's $1.4 Billion Goodwill Write-Down Reflects Previously Undisclosed Asset Deterioration [Accessibility Statement] Skip Navigation(NYSE: RAL)NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ralliant Corp. (NYSE: RAL) on behalf of shareholders concerning the company's February 4, 2026 disclosure of a $1.4 billion goodwill impairment charge in connection with its fourth-quarter 2025 earnings release. The impairment represents approxima ...

LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION [Accessibility Statement] Skip NavigationTime-Sensitive: Allegations Focus on Repeated Assurances Regarding Setrusumab EfficacyRARE INVESTOR ALERT"Investors deserve transparency about material risks that could affect their investments," stated Joseph E. Levi, Esq., managing partner of Levi & Korsinsky, LLP. "The adequacy of clinical trial risk disclosures is a fundamental issue for biopharm ...

LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION [Accessibility Statement] Skip NavigationShareholders Who Purchased INO Securities During Class Period Urged to Review OptionsNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP announces that a securities class action has been filed against Inovio Pharmaceuticals, Inc. (NASDAQ: INO).YOU MAY BE AFFECTED IF YOU:- Acquired shares during the Class Period- Lost money on your Inovio inves ...

Contact Levi & Korsinsky by April 14, 2026 Deadline to Join Class Action Against REGENXBIO Inc.(RGNX) [Accessibility Statement] Skip NavigationNEW YORK, Feb. 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in REGENXBIO Inc. ("REGENXBIO" or the "Company") (NASDAQ: RGNX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of REGENXBIO investors who were adversely affected by alleged securities fraud between February 9, 2022 and January 27, 202 ...